Wave Life Sciences Ltd (NASDAQ:WVE) – Research analysts at Svb Leerink issued their Q1 2020 earnings estimates for Wave Life Sciences in a note issued to investors on Thursday, December 5th. Svb Leerink analyst M. Foroohar expects that the company will post earnings per share of ($1.15) for the quarter. Svb Leerink also issued estimates for Wave Life Sciences’ Q2 2020 earnings at ($1.14) EPS, Q3 2020 earnings at ($1.14) EPS, Q4 2020 earnings at ($1.04) EPS and FY2020 earnings at ($4.47) EPS.
Wave Life Sciences (NASDAQ:WVE) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($1.48) EPS for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.14). Wave Life Sciences had a negative return on equity of 128.21% and a negative net margin of 1,015.84%. The company had revenue of $2.93 million for the quarter, compared to analyst estimates of $6.30 million.
Shares of Wave Life Sciences stock opened at $35.11 on Monday. The company has a quick ratio of 1.88, a current ratio of 1.88 and a debt-to-equity ratio of 0.26. Wave Life Sciences has a 12 month low of $17.59 and a 12 month high of $50.98. The business has a fifty day simple moving average of $28.73 and a 200 day simple moving average of $24.42. The stock has a market cap of $1.11 billion, a PE ratio of -6.94 and a beta of 0.91.
Several institutional investors and hedge funds have recently modified their holdings of the company. Janus Henderson Group PLC lifted its stake in Wave Life Sciences by 16.1% in the 2nd quarter. Janus Henderson Group PLC now owns 3,392,298 shares of the company’s stock worth $88,505,000 after acquiring an additional 470,402 shares in the last quarter. Athanor Capital LP bought a new position in shares of Wave Life Sciences during the 2nd quarter worth approximately $566,000. Swiss National Bank lifted its position in shares of Wave Life Sciences by 2.4% during the 2nd quarter. Swiss National Bank now owns 34,200 shares of the company’s stock worth $892,000 after buying an additional 800 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Wave Life Sciences by 8.7% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 115,769 shares of the company’s stock worth $3,021,000 after buying an additional 9,273 shares during the period. Finally, Virtus ETF Advisers LLC lifted its position in shares of Wave Life Sciences by 93.3% during the 2nd quarter. Virtus ETF Advisers LLC now owns 10,387 shares of the company’s stock worth $271,000 after buying an additional 5,014 shares during the period. Institutional investors own 90.00% of the company’s stock.
In other news, Director Gregory L. Verdine sold 30,039 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $30.63, for a total value of $920,094.57. Following the completion of the sale, the director now directly owns 36,009 shares in the company, valued at approximately $1,102,955.67. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Chandra Vargeese sold 6,000 shares of the firm’s stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $32.34, for a total value of $194,040.00. Company insiders own 39.70% of the company’s stock.
Wave Life Sciences Company Profile
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Featured Article: FTSE 100 Index
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.